Results 111 to 120 of about 130,309 (214)
Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne +6 more
wiley +1 more source
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Objectives To evaluate the incremental clinical value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG‐PET/CT) beyond contrast‐enhanced computed tomography (CECT) for primary staging of suspected high‐risk upper tract urothelial carcinoma (UTUC).
Renee A. G. Lijnen +8 more
wiley +1 more source
Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer
Background Two-deoxy-2-[fluorine-18]-fluoro-d-glucose (18F-FDG) positron emission tomography (PET) is useful for detecting malignant lesions; however, the clinical significance of cardiac 18F-FDG uptake in patients with cancer remains unclear.
Kosuke Hashimoto +9 more
doaj +1 more source
BackgroundProstate-specific membrane antigen (PSMA) ligand PET/CT has significantly improved prostate cancer (PCa) imaging. However, in patients with poorly differentiated PCa or neuroendocrine transdifferentiation, [18F]fluorodeoxyglucose ([18F]FDG) PET/
Cesare Michele Iacovitti +11 more
doaj +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Xiaojiang He,1,* Long Zhao,1,* Xiuyu Guo,1 Liang Zhao,2 Jing Wu,1 Jingxiong Huang,1 Long Sun,1 Chengrong Xie,3 Haojun Chen1 1Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Hospital of the First Affiliated Hospital of Xiamen ...
Sun L +7 more
core
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source
Background Brown adipose tissues (BAT) are highly vascularized, mitochondria-rich tissues involved in thermogenesis. Physiological [18F]fluorodeoxyglucose ([18F]FDG) uptake in BAT can be influenced by several factors, including the use of medications ...
John Kenneth V. Gacula +4 more
doaj +1 more source
Background Tuberculous pericarditis is the most common cause of pericardial disease in tuberculosis-endemic areas. Accurate and early diagnosis of tuberculous pericarditis is crucial due to its high mortality; however, the diagnostic accuracy of current ...
Xiaoqing Du, Feng Zhu, Qian You
doaj +1 more source

